Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

European Urology

Volumn 59, Issue 5, 2011, Pages 747-754

  Denmeade, Samuel R ^a,b,f   Egerdie, Blair ^c   Steinhoff, Gary ^d   Merchant, Rosemina ^b   Abi Habib, Ralph ^b   Pommerville, Peter ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Protox Therapeutics Inc   (Canada)

^c Urology Associates Urologic Medical Research   (Canada)

^d Dr Steinhoff Clinical Research   (Canada)

^e Can Med Clinical Research Inc   (Canada)

^f Cancer Research Building i ^*  (United States)

Author keywords

Benign prostatic hyperplasia; Intraprostatic; Lower urinary tract symptoms; Proaerolysin; Prostate specific antigen; Protease; Protein toxin

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTOXIN; PRX 302; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHILL; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; FLOW RATE; HEMATURIA; HUMAN; INJECTION SITE INFECTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; ORGAN SIZE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VOLUME; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE RETENTION;

AGED; AGED, 80 AND OVER; BACTERIAL TOXINS; CANADA; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PENILE ERECTION; PORE FORMING CYTOTOXIC PROTEINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; URODYNAMICS; UROLOGIC DISEASES;

EID: 79953249701     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2010.11.024     Document Type: Article

References (17)

1. C.G. Roehrborn, L. Marks, and R. Harkaway Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners Prost Canc Prost Dis 9 2006 30 34 (Pubitemid 43378865)
2. C.G. Roehrborn Benign prostatic hyperplasia: an overview Rev Urol 7 Suppl 9 2005 S3 14
3. H. Lepor, and Pathophysiology epidemiology, and natural history of benign prostatic hyperplasia Rev Urol 6 Suppl 9 2004 S3 10
4. F. Debruyne, J. Barkin, and P. van Erps Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia Eur Urol 46 2004 488 495 (Pubitemid 39200858)
5. H. Lepor The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia Rev Urol 8 Suppl 4 2006 S3 9
6. J.S. Sandhu, and E.D. Vaughan Jr. Combination therapy for the pharmacological management of benign prostatic hyperplasia: rationale and treatment options Drugs Aging 22 2005 901 912 (Pubitemid 41746573)
7. C. Deliveliotis, C. Liakouras, A. Delis, A. Skolarikos, J. Varkarakis, and V. Protogerou Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population Urol Res 32 2004 283 289 (Pubitemid 39222606)
8. R.C. Harkaway, and M.M. Issa Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia Prostate Cancer Prostatic Dis 9 2006 204 214 (Pubitemid 44317252)
9. S.P. Howard, and J.T. Buckley Activation of the hole-forming toxin aerolysin by extracellular processing J Bacteriol 163 1985 336 340 (Pubitemid 15012757)
10. J.T. Buckley Crossing three membranes. Channel formation by aerolysin FEBS Lett 307 1992 30 33
11. S.A. Williams, R.F. Merchant, E. Garrett-Mayer, J.T. Isaacs, J.T. Buckley, and S.R. Denmeade A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease J Natl Cancer Inst 99 2007 376 385 (Pubitemid 47073481)
12. L. Abrami, M. Fivaz, and E. Decroly The pore-forming toxin proaerolysin is activated by furin J Biol Chem 273 1998 32656 32661 (Pubitemid 28557648)
13. S.R. Denmeade, W. Lou, J. Malm, J. Lovgren, H. Lilja, and J.T. Isaacs Specific and efficient peptide substrates for assaying the proteolytic activity of prostate specific antigen Cancer Res 57 1997 4924 4930 (Pubitemid 27469004)
14. S.A. Williams, P. Singh, J.T. Isaacs, and S.R. Denmeade Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 67 2007 312 329
15. A. Mattiasson, L. Wagrell, and S. Schelin Five-year follow-up of feedback microwave thermotherapy versus TURP for clinical BPH: a prospective randomized multicenter study Urology 69 2007 91 96 (Pubitemid 46161719)
16. T.R.W. Hermann, A.J. Gross, D. Schultheiss, P.M. Kaufmann, U. Jonas, and M. Burchardt Transurethral microwave therapy for the treatment of BPH: still a challenger? World J Urol 24 2006 389 396 (Pubitemid 44304935)
17. C. Bouza, T. Lopez, A. Magro, L. Navalpotro, and J.M. Amate Systemic review and meta-analysis of transurethral needle ablation in symptomatic benign prostatic hyperplasia BMC Urol 6 2006 14 30